Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Gains from Investment Securities (2020 - 2026)

Cresco Labs filings provide 7 years of Gains from Investment Securities readings, the most recent being -$1.4 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 20.7% to -$1.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.1 million, a 21.09% decrease, with the full-year FY2025 number at $4.7 million, down 48.48% from a year prior.
  • Gains from Investment Securities hit -$1.4 million in Q1 2026 for Cresco Labs, down from $18.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $73.6 million in Q4 2023 to a low of -$42.6 million in Q4 2022.
  • Median Gains from Investment Securities over the past 5 years was $238000.0 (2024), compared with a mean of $4.8 million.
  • The widest YoY moves for Gains from Investment Securities: up 727.49% in 2022, down 1440.83% in 2022.
  • Cresco Labs' Gains from Investment Securities stood at -$42.6 million in 2022, then surged by 272.64% to $73.6 million in 2023, then plummeted by 110.67% to -$7.8 million in 2024, then surged by 334.88% to $18.4 million in 2025, then crashed by 107.46% to -$1.4 million in 2026.
  • The last three reported values for Gains from Investment Securities were -$1.4 million (Q1 2026), $18.4 million (Q4 2025), and -$2.9 million (Q3 2025) per Business Quant data.